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Abstract Neuronal pentraxin II (NPTX2) is the most
highly upregulated gene in the Parkinsonian substantia
nigra based on our whole genome expression proWling
results. We show here that it is a novel component of Lewy
bodies and Lewy neurites in sporadic Parkinson’s disease
(PD). NPTX2 is also known as the neuronal activity-regu-
lated protein (Narp), which is secreted and involved in
long-term neuronal plasticity. Narp further regulates
AMPA receptors which have been found to mediate highly
selective non-apoptotic cell death of dopaminergic neurons.
NPTX2/Narp is found in close association with alpha-syn-
uclein aggregates in both substantia nigra and cerebral cor-
tex in PD but unlike alpha-synuclein gene expression,
which is down-regulated in the Parkinsonian nigra, NPTX2
could represent a driver of the disease process. In view of
its profound (>800%) upregulation and its established role
in synaptic plasticity as well as dopaminergic nerve cell
death, NPTX2 is a very interesting novel player which is
likely to be involved in the pathway dysregulation which
underlies PD.
Keywords AMPA receptors · Cell death · Dementia · 
Expresssion proWling · Orexin/hypocretin system
Introduction
Neuronal pentraxins constitute a family of proteins that
are homologous to C-reactive and acute-phase proteins
in the immune system and are thought to be involved
in activity-dependent synaptic plasticity [1, 11, 32]. The
neuronal pentraxins (NPTX1, NPTX2) and the neuronal
pentraxin receptor were identiWed as synaptic proteins
that bind to aYnity columns of the snake venom toxin,
taipoxin which presynaptically blocks neurotransmission,
and the luminal calcium-binding protein TCBP49 [15].
NPTX2 [14] is also known as neuronal activity-regulated
pentraxin (Narp), which was Wrst identiWed as an immedi-
ate early gene responding to the induction of seizures in
rat hippocampus [31]. The expression of this protein is
regulated by synaptic activity and it induces the formation
of new excitatory synapses and the regulation of alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA)-type glutamate receptor clustering at established
synapses [7, 22, 23]. Importantly, dopaminergic neurons
are selectively susceptible to excitotoxicity mediated via
AMPA receptor activation with the resulting cell death
being non-apoptotic [5].
A second line of research that makes NPTX2 a highly
interesting gene in the context of Parkinson’s disease (PD)
research concerns its expression in hypothalamic nerve
cells that co-express hypocretin/orexin [3] and which are
prodigiously aVected by the neurodegeneration in PD.
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These nerve cells have been implicated in the sleep distur-
bances that are often found in PD patients [9, 30].
Using a whole genome expression dataset of the human
Parkinsonian nigra [19], we have identiWed NPTX2 as the
most highly upregulated gene in a cohort of sporadic PD
cases. Here we demonstrate that NPTX2 labels Lewy bod-
ies in paraYn sections and that there is dysregulation of
NPTX2 also in PD frontal cortex.
Materials and methods
Tissue samples from human SN and frontal cortex
Some of the sporadic PD cases used in this study and
several controls have been described previously [6, 19,
20]. Information on the cases employed for this project is
provided in Supplemental Table. Brain tissue was
obtained from the UK Parkinson’s Disease Society Brain
Bank at Imperial College London. The diagnostic work
was performed in the Department of Neuropathology fol-
lowing international neuropathological consensus crite-
ria for PD (http://www.ICDNS.org) which require use of
alpha-synuclein as a molecular diagnostic marker. Ethics
committee approval was available for all human tissue
work of this study. For the dissection of the substantia
nigra tissue (medial and lateral nigra were prepared sepa-
rately), the portion of the midbrain containing the sub-
stantia nigra was separated from the brainstem distal to
the mamillary bodies (45° angle cut) at the level of the
third cranial nerve and the superior colliculi. A slice
approximately 5 mm in depth was prepared containing
both SN and the cross-sectioned red nucleus at the level
of its greatest diameter. Then, the SN was dissected from
the surrounding nuclei and the pars reticulata. Once the
SN was isolated, it was divided into two portions, the
medial SN and the lateral SN. In all cases where frontal
lobe was used, the superior frontal gyrus was sampled at
the same level.
Quantitative real-time polymerase chain reaction
Total RNA was extracted from PD and control cases and
transcribed using the RETROscript® kit (Applied Bio-
systems, Warrington, UK) following the manufacturer’s
protocol. Primers for the internal control genes were as
before [19]. Predesigned Taqman primers for NPTX2
(Hs00383983_m1) were purchased (Applied Biosystems)
and Taqman mastermix (Applied Biosystems) was used.
Each reaction was run in triplicate using an ABI PRISM™
7700 Sequence Detector (Applied Biosystems). For every
gene tested, a negative control was run without cDNA
template. Data analysis for real-time PCR (DART-PCR
Version 1.0; [25]) was used to determine relative diVer-
ences in NPTX2 mRNA expression between PD cases and
controls (also see Supplemental Figure 1).
In situ hybridization (ISH)
ISH was performed using radioactive oligonucleotide
probes as described previously [18, 29] Oligonucleotides
were designed using NetPrimer software (Premier, BioSoft
International, http://www.premierbiosoft.com). Two oligo-
nucleotides complementary to NPTX2 mRNA at nts 899–
932 (AGCCACAGGCAGATGGTGAAGGCGTACAGC
TCAG—probe A) and nts 1364–1397 (TCGACGTTATT
GTCCACCCACGG-GATGATGTTGC—probe B) were
synthesized (Sigma Genosys, Poole, UK). Oligonucleotides
were radioactively end-labelled with 35S-dATP (Perkin-
Elmer, UK) using terminal deoxynucleotidyl transferase
(Promega, UK).
Snap frozen, unWxed post-mortem tissue blocks of the
frontal cortex and SN were cut on a cryostat (12 m),
collected onto Superfrost Plus slides (VWR) and stored
at  ¡80°C. Before use, tissue sections were Wxed for
5 min in fresh 4% paraformaldehyde in 0.1 M phosphate
buVer (pH 7.4). Pre-hybridisation treatment included
acetylation in 0.25 M acetic anhydride/0.1 M triethanola-
mine, dehydration in graded alcohol (70–100% ethanols)
and delipidation in 100% chloroform. Hybridisation with
the oligonucleotide probe was performed overnight at
37°C. Post-hybridisation sections were washed in stan-
dard saline citrate solutions with increasing stringencies.
The sections were dehydrated rapidly through graded
alcohols (70–100% ethanol), air-dried, dipped in autora-
diographic emulsion (LM1, GE Healthcare, Amersham,
UK) and exposed for 5–6 weeks. The autoradiographic
emulsion was developed, sections were counterstained
with toluidine blue (VWR) for Nissl substance and
mounted for visualisation using bright Weld microscopy
for the counterstain and epi-polarized illumination for
the silver grains of the autoradiographic emulsion. Con-
trol slides run to check for speciWcity of hybridization
included competition with an excess of oligonucleotide
(250 times) and the use of two probes to diVerent por-
tions of the mRNA of interest which produced identical
patterns of signal. Black and white photographs of emul-
sion-coated sections were taken using a microscope pro-
vided with a Hamamatsu C4742–95 digital camera
(Herrsching, Germany) and HiPic software (Herrsching)
to capture images. Digital colour images were captured
with a Retiga 1300 monochrome 12-bit camera using a
color option provided by a RGB-HM-S Wlter (QImaging,
Burnaby, BC, Canada) and QCapture 1.1.6 software
(QImaging). Adobe Photoshop was used to assemble
images.Acta Neuropathol (2008) 115:471–478  473
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Immunohistochemistry
ParaYn embedded tissue sections (8 m) were used for all
stainings. No antigen retrieval was required for NPTX2
whereas for alpha-synuclein (SNCA) antibody staining sec-
tions were treated with 80% formic acid for 60 min [24].
Adjacent sections from SN were stained with goat poly-
clonal anti-NPTX2 antibody (NP2 N-20, sc-12125; Santa
Cruz Biotechnology Inc.; 1:25) and mouse monoclonal
anti-SNCA (BD Transduction Laboratories, catalogue
number 610787; 1:1,000) overnight (4°C). Secondary
antibodies used were gG-HRP (sc-2020; Santa Cruz Bio-
technology Inc.; 1:100) and biotinylated horse anti-mouse
(B-2000; Vector Laboratories, 1:100), respectively. The
ABC kit (Elite 6100, Vector Laboratories) was used for
visualisation using 3,3-diaminobenzidine tetrahydrochloride
(0.02%; Sigma, UK). Sections were counter-stained in
Mayer’s haemalum.
For Xuorescence microscopy, anti-SNCA (1:1,000) and
anti-NPTX2 (1:25) were added to the sections sequentially
(each was incubated overnight at 4°C). For the detection of
the primary antibodies, sections were rinsed in 0.1 M Tris
buVered saline (TBS) and then incubated with either the
goat anti-rabbit IgG tagged with Alexa Fluor 546 (red) for
1 h at room temperature or the biotinylated anti-mouse anti-
body (Vector Laboratories 1:100) for 1 hour followed by
incubation with streptavidin Alex Fluor 488 (green) for 1 h
at room temperature. Finally, tissue sections were rinsed in
TBS and incubated in sudan black for 10 min before
mounting in 80% Tris-buVered glycerol.
Fig. 1 Neuronal pentraxin II 
(NPTX2) is strongly upregulated 
in substantia nigra and cerebral 
cortex of PD patients. a NPTX2 
immunocytochemistry demon-
strating speciWc staining of 
Lewy bodies in a dopaminergic 
neuron. b Western blotting 
conWrms speciWcity of the anti-
NPTX2 antibody. c qRT-PCR 
shows highly increased levels of 
NPTX2 mRNA in substantia 
nigra and, to a lesser extent, in 
frontal cortex. The arbitrary 
units along the ordinate repre-
sent relative fold changes [25]. 
The control value is 1; error bars 
indicate SEM. d, e In situ 
hybridisation demonstrates 
NPTX2 mRNA expression in 
nerve cells as well as glia in both 
substantia nigra and frontal cor-
tex. Labelling is also found over 
non-pigmented neurons (arrow 
in d, SN). The arrows in e mark 
glial cells (cortex). In addition, 
there is autoradiographic signal 
in the neuropil (asterisks) which 
would be in keeping with the 
presumed dendritic expression 
of NPTX2 mRNA. f NPTX2 
immunocytochemistry of corti-
cal neuropil reveals occasional 
intercellular patches of “arbor-
ised” labelling also possibly 
suggestive of a dendritic locali-
sation (asterisks). The arrow 
points to a NPTX2 
immunoreactive glial cell. 
Counterstaining in a and f, 
haemalum, and toluidine blue in 
d. Scale bars: 20 m (a, f), 
50 m (d), and 100 m (e)474 Acta Neuropathol (2008) 115:471–478
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Western blotting
Snap frozen midbrain tissue samples containing SN from
PD and control cases were homogenized with RIPA
buVer (pH 8), heated to 70°C for 10 min and subse-
quently centrifuged (13,000 rpm, 10 min). The protein
supernatant was removed and the concentration of pro-
tein determined (BIO-RAD protein reagent; BIO-RAD,
UK) using a spectrophotometer. Denaturing gels were
run using 30 g of protein from each sample in 19.5 l
RIPA buVer, 3 l -mercaptoethanol and 7.5 l lithium
dodecyl sulphate sample buVer (Invitrogen, UK).
NuPAGE Bis–Tris 4–12% polyacrylamide gels (Invitro-
gen) were run in NuPage SDS running buVer (Invitro-
gen). Gels were blotted onto nitrocellulose membranes
(Invitrogen), immersed in NuPage LDS transfer buVer
(Invitrogen) in a cold room (4°C) overnight applying
30 V. Successful protein transfer was veriWed by staining
the membrane in Ponceau S (VWR, UK) for 10 min.
Prior to overnight incubation in polyclonal goat antibody
to NPTX2 (N-20), membranes were washed in phosphate
buVered saline (PBS) containing 0.1% Tween 20 and
subsequently rinsed in PBS/0.1% Tween 20 containing
5% skimmed milk (blocking step) for 30 min. Incubation
with the secondary antibody coupled to horseradish per-
oxidase (1:5,000; Vector Labs, UK) was carried out for
1 h at room temperature. Visualization of antibody bind-
ing using enhanced chemilluminescence (ECL; Amer-
sham Biosciences, UK) was performed according to the
manufacturer’s instructions.
Semi-quantitative ratings
The NPTX2 labelled SN sections were examined by two
independent observers blinded to the identity of the respec-
tive cases. The occurrence of NPTX2 immunoreactive pro-
Wles in the SN was scored for the overall burden of NPTX2
immunoreactive deposits using a seven-point scale ranging
Fig. 2 Co-localisation of NPTX2 and alpha-synuclein. a, b NPTX2
and alpha-synuclein immunolabelling of adjacent tissue sections dem-
onstrates signiWcant but not complete overlap between the two pro-
teins. The large arrow in a denotes the same Lewy body-containing
dopaminergic nigral neuron. Small granular cytoplasmic deposits
showing alpha-synuclein immunoreactivity in some nerve cells
(arrows in b) are NPTX2 negative. These aggresomes are sometimes
diYcult to distinguish from neuromelanin granules based on staining
alone but their cytoplasmic distribution is also diVerent from the latter.
In contrast, Lewy neurites are double-labelled (arrow head in b). Neu-
romelanin (asterisks in a) is unstained. c, d, e Dual immunoXuorecence
demonstrates co-localisation of neuronal pentraxin II (red,  c) and
alpha-synuclein (green, d). Double-labelled structures (arrows in c)
light up in yellow in the overlay (e). Scale bar: 40 m (a, b), and 80 m
(c–e), respectivelyActa Neuropathol (2008) 115:471–478  475
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from 0–0.5 to 3 (absent to severe). Correlation analysis
(Spearman; Sigmatstat 2.03) was conducted within the PD
cohort for NPTX2 mRNA expression (log 2 microarray
data) and the corresponding semi-quantitative immunocy-
tochemical results.
Results
NPTX2 is a novel component of Lewy bodies
We demonstrate here that NPTX2 protein in the Parkin-
sonian substantia nigra localizes to Lewy bodies, Lewy
neurites and some glial cells. NPTX2 is the most upregu-
lated gene in our microarray data set [19]. It shows the
greatest diVerence between disease and control nigrae
(probe 213479_at, P = 4.60051E¡07, diVerential expres-
sion, DElog 2, 3.0036217 which is equivalent to >800%).
Many neurons show more than one NPTX2 immunoreac-
tive LB (Fig. 1a). Western blotting conWrmed speciWcity
of the antibody revealing a band, which corresponds to
the NPTX2 monomer (47 kDa; Fig. 1b). Very strong
upregulation of NPTX2 mRNA expression in PD was
conWrmed by means of quantitative real time-PCR
(Fig. 1c).
Localisation of NPTX2 and SNCA protein
In situ hybridisation revealed expression of NPTX2 mRNA
in nerve cells as well as glia in both SN and frontal cortex,
respectively (Fig. 1d, e). NPTX2 immunoreactive LBs
were also observed in the frontal cortex and there were
ramiWed (“arborised”) NPTX2 positive proWles of cell pro-
cesses in the neuropil (Fig. 1f). Analysis of adjacent tissue
sections demonstrated co-localisation of NPTX2 and
SNCA in the same nerve cells (Fig. 2a, b). This was con-
Wrmed by dual immunoXuorescence (Fig. 2c–e). Overall,
NPTX2 immunoreactive neuronal deposits mapped very
closely to alpha-synuclein aggregates, both cellularly and
subcellulary, and NPTX2 was also observed in incidental
Lewy bodies (for a summary of cases used see Supplemen-
tal Table of Electronic Supplementary Material). In con-
trast, no NPTX2 immunoreactive intracellular aggregates
were observed in two cases of tauopathy, i.e. progressive
supranuclear palsy, where alpha-synuclein deposits are also
not found. However, not all SNCA immunoreactive proWles
were NPTX2 positive, i.e. the number of SNCA labelled
nerve cells outnumbered that of NPTX2 stained ones (about
2–3:1). In addition, in some nerve cells, SNCA immunopo-
sitivity was observed as small granular cytoplasmic depos-
its (“aggresomes”) that lacked NPTX2 immunoreactivity
(Fig. 2a, b). However, NPTX2 immunoepitopes were
found to decorate the halo of LBs more distinctly than
alpha-synuclein (Fig. 3). Strongly NPTX2 immunoreactive
Lewy neurites (Fig. 3) were also found. Cases with high
levels of NPTX2 protein expression showed a larger alpha-
synuclein burden. We estimate that about one-third of the
alpha-synuclein immunoreactive protein deposits also stain
for NPTX2. Labelling of normal appearing axons by
NPTX2 was widespread in both PD (Fig. 3) and control
brains. Glial cytoplasmic (Papp-Lantos) inclusions of mul-
tiple system atrophy (MSA) were NPTX2 positive (not
shown) and in PD a sizeable number of glial cells expressed
NPTX2 protein that appeared to be SNCA negative
(Fig. 3). Correlation analysis for NPTX2 microarray
expression data and the corresponding semi-quantitative
immunocytochemical case ratings showed a signiWcant cor-
relation (r = 0.970,  P < 0.001; Table 1). However, there
was no association between NPTX2 expression and dura-
tion of the disease. 
Discussion
The most signiWcant Wnding of this study is the striking
presence of NPTX2 in classical Lewy bodies and in Lewy
neurites. Experimental studies have demonstrated that
Narp, the rat homologue of NPTX2, is important in neuro-
nal development, promoting neuronal migration, synapse
formation [1, 8] and neurite outgrowth [31]. Studies in neu-
ronal pentraxin I and neuronal pentraxin II knockout mice
have demonstrated a role in early synaptic reWnements in
the retina and dorsal lateral geniculate nucleus during
development [1]. It has also been suggested that Narp’s role
in synaptic plasticity may underlie the long-lasting aversive
eVects of drug withdrawal [10, 26]. These functions of the
NPTX2 gene product and its dendritic expression in the
cerebral cortex [17] are of special interest in relation to our
Wnding that NPTX2 immunoreactivity was also occasion-
ally present in the cortical neuropil where it had a ramiWed
appearance reminiscent of dendritic arbors.
There is limited knowledge on the NPTX2 pathway
(Fig. 4). Known physiological functions of NPTX2 include
a role in the induction of AMPA receptor clustering [7].
NPTX2, NPTX1 and the GRIA3 subunit of AMPA recep-
tors are all upregulated in our dataset. All other AMPA
subunits and the receptor for NPTX2, NPTXR are down-
regulated. Two additional genes whose functions may be
associated with AMPA receptors in dopaminergic neurons
are also highly dysregulated in PD, NSF (N-ethylmaleimide
sensitive fusion protein; 202395_at, P = 1.18252E¡05,
DElog 2 = ¡1.389396766) and Calcyon (dopamine receptor
D1 interacting protein, 219896_at, P = 4.12902E¡06,
DElog 2 =¡2.049585553). NSF binds the AMPA receptor
GluR2 subunit and acts to disrupt GluR2-PICK1 interac-
tions [28]; it may play a role in AMPA receptor traYcking476 Acta Neuropathol (2008) 115:471–478
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and stabilization. Calcyon is co-expressed in a number of
D1 dopamine receptor-positive neurons in brain and, like
D1 dopamine receptors, is found in dendritic spines [16].
We also found NPTX2 in glial cells possibly including
microglia. However, staining of glia was only present in a
subpopulation of cells while neuronal cell processes
appeared to be consistently labelled. Why exactly NPTX2
accumulates in Lewy bodies remains unclear at present.
However, it is conceivable that NPTX2 is involved in the
uptake of synaptic material. Synaptic dysfunction in PD is
very signiWcant as suggested by our microarray experi-
ments (unpublished data). The presence of NPTX2 in only
a subset of Lewy bodies and its association with their
“crenellated surface” shown in Fig. 3 as well as NPTX2
immunoreactive “bridges” between Lewy bodies might
indicate a role of NPTX2 in Lewy body growth.
Many PD patients also show non-motor symptoms such
as hallucinations, depression, autonomic dysfunction and
Fig. 3 Morphology of neuronal pentraxin II immunoreactive deposits
in the Parkinsonian substantia nigra. a Lewy bodies are labelled which
often show a crennelated surface (also see c). Arrows of the inset point
to NPTX2 labelled connections/“bridges” between small Lewy bodies.
Cross-sectioned axon bundles in white matter are numerous (longer
arrows). b Arrows point to Lewy neurites in the substantia nigra. c
NPTX2 is present in pre-Lewy bodies and glial cells. Labelling can be
seen inside the cytoplasm of nerve cells in the neighbourhood and often
directly attached to mature Lewy bodies (long arrows). Note the cren-
ellated surface of compacted NPTX2 deposits (centre and Lewy body
at the bottom of the Wgure) due to hair-like projections, which radiate
into the cytoplasm. NPTX2 immunoreactivity is also present in glial
cells. A subset of astrocytes as well as possibly microglia appear to be
labelled (small arrows). The short arrow in the lower left points to what
appears to be nuclear immunoreactivity. Scale bars: 40 (a), 50 (b) and
30 (c) m, respectively
Table 1 Correlation analysis for NPTX2 microarray expression data
and the corresponding semi-quantitative immunocytochemical ratings
for eight of the PD cases
Case 
number
Expression 
NPTX2 mRNA (log 2)
Semi-quantitative 
ratings NPTX2 IR in SN
2 7.278105587 1
3 9.800657274 3
6 8.739679364 1.5
7 8.44508108 1.5
9 3.418203444 0.5
12 7.980139578 1
14 8.965264821 2
15 6.414495823 1Acta Neuropathol (2008) 115:471–478  477
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sleep-disturbances. All these symptoms are present in nar-
colepsy where there is loss of orexin (hypocretin) produc-
ing nerve cells in the hypothalamus [2, 30]. It is noteworthy
therefore that the same population of neurons shows mas-
sive cell loss in PD as shown recently [9, 30]. In addition,
Thannickal et al. observed a signiWcant correlation with the
clinical stage of PD [30]. It is intriguing that orexin neurons
of the hypothalamus demonstrate robust expression of Narp
in the rat [27].
The relationship between NPTX2 and cell death
deserves further study. All subunits of the NMDA, AMPA
and kainate classes of glutamate receptors and a set of
NMDA receptor-associated intracellular proteins are
expressed in the human substantia nigra pars compacta, and
may play a role in glutamate regulation of dopaminergic
activity and/or release [21]. AMPA in turn has been discov-
ered to be a mediator of selective non-apoptotic cell death
in dopaminergic neurons [4]. The latter diVers ultrastructur-
ally from both neuronal apoptosis and typical excitotoxic-
ity. Importantly, this mode of cell death is independent of
caspase activity and does not have the morphological
appearance of classical apoptosis. The Wndings are thus in
keeping with our old postulate that nigral neurons are likely
to die of a mechanism other than classical apoptosis and
that aposklesis (“withering”) may be a more appropriate
term [12, 13]. The involvement of NPTX2 in cell death
mechanisms is additionally supported by studies on the
eVect of ceramide, which activates TNF-pathways [4].
Therefore, NPTX2/Narp has to be considered a new impor-
tant gene in PD dysregulation which may be linked to both
motor dysfunction caused by nigral dopaminergic nerve
cell death in the midbrain and dementia due to synaptic
changes in the cerebral cortex.
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